obesity companies

Jun 15, 2026

Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy. Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026). Several companies, such a...

Oct 31, 2025

In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025,...

May 12, 2025

The pharmaceutical industry is witnessing a seismic shift, fueled by the meteoric rise of GLP-1 agonist molecules. Once a niche class of diabetes drugs, GLP-1 agonists have become the cornerstone of a global race to conquer obesity, a disease that has more than doubled in prevalence since 1990 and now affects over ...

Mar 26, 2025

Obesity is a chronic disease reaching alarming levels worldwide, leading to diabetes, cardiovascular disease, and metabolic disorders. It results from a mix of genetic, environmental, and lifestyle factors. Understanding what are the reasons for obesity—poor diet, inactivity, and hormonal imbalances—is crucial. Key...

Mar 17, 2025

The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy. These industry titans are redefining the weight loss drug market with groundbreaking GLP-1 therapies. Novo Nordisk’s WEGOVY (semaglutide) and E...

Mar 14, 2025

Obesity is the second most common cause of preventable death, associated with the risk of developing inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. ...

Mar 12, 2025

Obesity ranks as the second leading cause of preventable death, linked to the risk of inflammatory conditions that are directly and indirectly related to cardiovascular disease, diabetes, respiratory issues, psychological problems, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. This poses a majo...

Mar 12, 2025

With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...

Mar 12, 2025

Obesity is the second leading cause of preventable death and is linked to numerous inflammatory conditions, which contribute to diseases like cardiovascular disease, diabetes, respiratory issues, mental health disorders, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This poses a significant p...

Mar 12, 2025

Obesity isn't just a personal struggle; it's a worldwide epidemic affecting over 1 billion people. This alarming statistic highlights an urgent need for effective interventions, as obesity dramatically raises the risk of life-threatening conditions like type 2 diabetes, heart disease, sleep apnea, and even certain ...